Illumina, Inc. announced on December 4, 2024, a licensing agreement with Synaffix B.V., a Lonza company, for its patented metal-free click chemistry technology. This technology will be integrated into certain Illumina next-generation sequencing (NGS) products.
Synaffix's bicyclononyne (BCN) probe, known for its highly selective generation of site-specific and stable antibody-drug conjugates, offers unique chemical coupling properties. This integration is expected to contribute to making large-scale, whole-genome sequencing more accessible.
The agreement underscores Illumina's commitment to enhancing its core sequencing capabilities through strategic technology partnerships. This move aims to improve the efficiency and applicability of its NGS platforms across various research and therapeutic areas.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.